我们的团队

同一个愿景,同一项使命,同一个团队

我们的领导

Zhou Lihan

联合创始人兼首席执行官

Zou Ruiyang

联合创始人兼首席技术官

Isaac Ho

首席投资官

Choo Beng Lor

首席财务官

Francine Wong

人力资源部总监

David Capes

全球创新负责人

Eugene Wong

并购高级副总裁

Teo Cher Hwa

健康创新交付部高级副总裁兼首席战略官

Dan Headon

营销高级副总裁

Cheng He

研发部副总裁

Cheong Jit Kong博士

外部创新部负责人

Zhao Pan

产品副总裁

Tang Yew Chung

科学/医学事务助理副总裁

Jeremiah Decosta

生产和法规事务副总裁

Zhou Qiumei

觅瑞中国制造和法规事务部副总裁

Larbi Gallagher

战略与增长运营副总裁

Ray ONG

商业运营副总裁

Guy Afseth

觅瑞美国业务开发部主管

Yoong Li-Foong

觅瑞日本经理助理兼代表董事

Martin Law

觅瑞香港董事总经理

Vitoria Owyong

法律与投资者事务副总裁

我们的顾问

我们的科学顾问委员会 (SAB) 从科学和技术的角度对我们的研发活动和战略提供外部咨询与建议。

MiRXES (觅瑞) 科学顾问委员会由 觅瑞 联合创始人兼首席科学顾问朱兴奋教授担任主席。

Prof. Too Heng-Phon

PhD

• Associate Professor of Biochemistry, National University of Singapore

• Associate Professor of Chemical and Biomolecular Engineering, National University of Singapore

• Co-founder & Chief Scientific Advisor, MiRXES

Prof. Frank Slack

PhD

• Shields Warren Mallinckrodt Professor of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center

• Director, Harvard Medical School Initiative for RNA Medicine at Beth Israel Deaconess Medical Center

• Co-discoverer of the second known microRNA and the first human microRNA

Prof. Chng Wee Joo

MB ChB, PhD, MRCP, DipRCPath, MRCPath

• Director, National University Cancer Institute, National University Health System

• Group Director of Research, National University Health System

• Deputy Director & Senior Principal Investigator, Cancer Science Institute, Singapore

• Vice Dean of Research & Provost’s Chair Professor, Yong Loo Lin School of Medicine, National University of Singapore

• Chief Medical Advisor, MiRXES

Prof. Lam Kong Peng

PhD

• Professor of Microbiology and Immunology, National University of Singapore

• Executive Director, Singapore Immunology Network, A*STAR

Prof. Takahiro Ochiya

PhD

• Professor of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University

• Chief Scientific Officer, Theoria Science

• President, Japanese Society for Extracellular Vesicles

Prof. Yeoh Khay Guan

MBBS, MMed, FRCP (London), FRCP (Glasg), FAMS

• Irene Tan Liang Kheng Professor in Medicine and Oncology, National University of Singapore

• Senior Consultant, Gastroenterology and Hepatology, National University Hospital

• Lead Principal Investigator, Singapore Gastric Cancer Consortium

• Chairman, National Colorectal Cancer Screening Committee, Health Promotion Board, Ministry of Health, Singapore

• Chief Executive, National University Health System

• Senior Vice President (Health Affairs), National University of Singapore

Dr. Holger Heyn

PhD

• Leader, Single Cell Genomics Team, Spanish National Centre for Genomic Analysis (CNAG-CRG), Barcelona, Spain

• Scientific Co-founder, Omniscope

Prof. Tony Mok

BMSc, MD, FRCP(C), FRCP(Edin), FRCP(Lond), FHKCP, FHKAM(Medicine), FASCO, Member of ASHK

• Chairman of the Department of Clinical Oncology, The Chinese University of Hong Kong

• Li Shu Fan Professor of Clinical Oncology, The Chinese University of Hong Kong

• Past President, International Association for the Study of Lung Cancer (IASLC)

版权所有 © 2022 MiRXES Pte Ltd. 保留所有权利。| 隐私政策
Scroll to Top

Zhou Lihan

Ph.D.

Co-founder & Chief Executive Officer

Zhou Lihan is the Co-founder and Chief Executive Officer of MiRXES. Lihan led MiRXES’ growth from a 3-man start-up in Singapore to a leader in RNA technology and disease early detection with operations globally.

Prior to founding MiRXES, Lihan led a research team at the Bioprocessing Technology Institute, A*STAR to develop a novel microRNA qPCR assay platform for biomarker and therapeutic target discovery. In 2015, Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35.

Lihan obtained his Ph.D. in Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. Lihan has authored and co-authored more than 20 peer-reviewed publications and several patent applications.

Zou Ruiyang

Ph.D.

Co-founder & Chief Technology Officer

Zou Ruiyang is Co-founder and Chief Technology Officer of MiRXES. Ruiyang is responsible for MiRXES’s technology and diagnostic test development, and also oversees MiRXES’s China operations.

Prior to founding MiRXES, he was the Head of Bioinformatics at the MicroRNA Signature Identification Center, A*STAR. Ruiyang has a passion for science and is continuously innovating to discover technology that can be developed to practical applications that can be delivered to the public.

Ruiyang has a PhD in Chemical and Pharmaceutical Engineering from Singapore-MIT Alliance (NUS-MIT), Singapore. He also successfully completed his dual degree in 2007 where he attained Bachelor of Science, Molecular Science and Engineering, Nankai University, Tianjin, P. R. China, and Bachelor of Engineering, Molecular Science and Engineering, Tianjin University, Tianjin, P. R. China. Ruiyang has co-authored more than 10 publications and has eight patents and applications.

Isaac Ho

Chief Investment Officer

Isaac Ho is Chief Investment Officer of MiRXES where he oversees corporate development, investor relations as well as builds strategic partnerships with key healthcare players and financial institutions.

Prior to MiRXES, Isaac founded Singapore Health, and subsequently VentureCraft Group, a Singapore government accredited co-investment partner and incubator in the healthcare and biomedical sciences sector. He is a veteran in entrepreneurship, investment, and business management. Under his leadership, Venturecraft Group was appointed as an accelerator under SPRING Singapore’s Sector Specific Accelerator Program for Biomedical Sciences.

Isaac graduated from Deakin University with a Bachelor’s Degree in Commerce (Marketing and Management).

Choo Beng Lor

Chief Financial Officer

Choo Beng Lor is the Chief Financial Officer of MiRXES and is responsible for matters relating to finance, internal controls, compliance, corporate management and investor relations.

He was previously with Zheneng Jinjiang Environment Holding Company Limited where he was the Financial Controller overseeing matters relating to financial management and reporting, compliance with post-listing obligations. Prior to that, Beng Lor spent 11 years being a CFO for companies including Cima NanoTech Pte Ltd, Sound Global Ltd and Sino Chemical Holdings Pte Ltd.

Beng Lor graduated with a Bachelor of Accountancy from Nanyang Technological University, Singapore. He is a Chartered Accountant of the Institute of Singapore Chartered Accountants.

Francine Wong

AVP, Human Resource

Francine Wong is Assistant Vice President, Human Resource at MiRXES where she is responsible for developing and executing HR strategy in support of the business plan and strategic direction of the organization, in the areas of talent management, organizational development, performance & rewards, and learning & development.

She was previously the APAC Regional HR Director at A. Menarini Asia Pacific where she oversaw the HR function for 13 markets across the Asia Pacific region. Francine has diverse industry experience in logistics, engineering and banking, with bulk of her experience in healthcare, where she was the HR Leader, ASEAN at GE Healthcare and Director – Strategic HR Business Partner for Asia Growth Markets at ResMed. At ResMed, she was part of the Global HR Leadership Team and helped to grow the manufacturing hub fourfold and supported its expansion.

Francine graduated with a Bachelor of Business degree majoring in Human Resource Consulting from Nanyang Technological University and holds an MBA from the University of Manchester.

David Capes

Ph.D.

SVP, Operations

David Capes is Senior Vice President, Operations at MiRXES where he is responsible for the transformation of MiRXES into a global innovation enterprise.

David has over 31 years of extensive biomedical technology industry experience across all facets of general management and strategy, research and development, innovation, organic and inorganic opportunity identification and development, quality management, regulatory affairs management, manufacturing and sales. He was previously the Vice President for R&D for Greater Asia in Becton-Dickinson (BD) where he led the strategic innovation team and was instrumental in establishing the idea portfolio management for their new product development (NPD) portfolio. He was phenomenal in leading overachievement of the revenue target of innovation to NPD project approvals by five-fold. Prior to BD, he held senior management roles in Pathway Biomed and Rockeby Biomed.

David holds a Ph.D. in Pharmacy from Curtin University, and has authored and co-authored more than 54 publications and has two U.S. patents.

Teo Cher Hwa

SVP, Health Innovation Delivery Chief of Staff

Teo Cher Hwa is the Senior Vice President (SVP), Health Innovation Delivery and Chief of Staff at MiRXES. In his role as SVP, Health Innovation Delivery, Cher Hwa will help to embed MiRXES into the Singapore healthcare system through downstream market access efforts by driving adoption of MiRXES’s products.

Additionally as Chief of Staff, he will assist MiRXES’s Co-founder and CEO, Dr. Zhou Lihan in overseeing strategic initiatives from development to successful execution as well as working closely with functional heads in decision-making, program management & initiative implementation.

Cher Hwa has over 20 years of experience in grant funding, technology transfer, product development, and commercializing innovative technologies in telecommunications and biomedical devices. He was previously the Director of National Health Innovation Centre Singapore and was also their founding member. Prior to that, Cher Hwa was Vice President of the Communications & Healthcare Cluster at A*Star’s A*ccelerate Technologies where he oversaw technology transfer activities such as IP management, licensing, industry collaboration and translational funding projects in the MedTech and communications sectors.

Cher Hwa holds a Bachelor of Engineering (First Class Hons) in Electronic Engineering from the University of Sheffield and an MBA from the University of Manchester.

Dan Headon

SVP, Marketing

Dan Headon is the Senior Vice President (SVP), Marketing at MiRXES. In his role as SP, Marketing, Dan will raise the awareness of MiRXES’s products to patients and customers by partnering closely with the Product, Commercial Operations and Medical Affairs’ teams in launching new products and refining the marketing strategy for MiRXES’s existing products.

Dan has more than 30 years of extensive experience in the biotechnology sector working for companies such as Biotech Australia, Millipore, Applied Biosystems and Illumina. Prior to joining MiRXES, he was the Director of Marketing for APAC at Illumina from 2008 to 2017, where he scaled the APAC marketing function from three to over 50 staff over a period of 10 years and contributed towards Illumina’s revenue growth in the region from USD 30 million per annum to over USD 500 million through a series of innovative marketing strategies.

Dan holds a Bachelor of Science degree from Macquarie University and a Graduate Diploma of Marketing from Monash University.

Cheng He

Ph.D.

VP, Research & Development

Cheng He is Vice President, Research & Development at MiRXES where he leads research projects to discover and develop new microRNA biomarkers in tissues, cells and biofluids, as well as productize cell-free microRNA biomarkers into liquid biopsy assay.

Prior to this, Cheng He was a research scientist at Bioprocessing Technology Institute (BTI), A*STAR. Cheng He strives to solve healthcare problems with innovative technologies and has worked on multi-disciplinary fields including the development of nanowire sensors and mRNA clinical assay for cancer prognosis. He is flexible and adaptable with experience ranging from upstream R&D to downstream productization.

Cheng He holds a PhD in Electrical Engineering, National University of Singapore and a Masters in Material Science from MIT, as well as a Bachelor in Bioengineering from Nanyang Technological University.

Cheong Jit Kong

Ph.D.

Head, External Innovation

Cheong Jit Kong is the Head of External Innovation at MiRXES and is responsible for the overall external R&D stakeholder engagement in key markets. He also supports MiRXES’ global clinical/scientific studies to generate scientific evidence and gather real-world clinical data. Additionally, Jit Kong serves concurrently as a Principal Investigator, Research Assistant Professor and Director of the NUS ncRNA Core Facility at NUS Yong Loo Lin School of Medicine.

Jit Kong is a recipient of multiple national and international research grants. He has extensive experience in signal transduction cascades in cancer biology, animal models of cancers, anti-cancer drug discovery as well as high-throughput miRNA expression screens.

Jit Kong graduated from a PhD program jointly administered by the National University of Singapore (NUS) and Harvard Medical School (HMS), Harvard University (U.S.A), where he was under the guidance of Professors Stephen Hsu I-Hong and Joseph Bonventre. He subsequently trained as a Singapore Millennium Foundation Postdoctoral Fellow at Prof David Virshup’s laboratory at Duke-NUS Medical School.

Zhao Pan

Ph.D.

VP, Genomics

Zhao Pan is the Vice President, Genomics at MiRXES where she leads the overall strategy in MiRXES’s product and service pipelines as well as oversees the product lifecycle management.

Previously, Pan co-founded and was the Chief Commercial Officer of Lucence Diagnostics. Prior to this, she had experience in business development and field application in companies including Vishuo Biomedical and Vela Diagnostics. Pan believes in empowering physicians to improve patient outcome, and is an advocate for precision medicine, genetic testing and disease early detection.

Pan holds a PhD in Molecular and Microbiology from National University of Singapore Graduate School, and has recently obtained her Masters in Medical Genetics from Chinese University of Hong Kong (CUHK), Department of Obstetrics and Gynecology, Prince of Wales Hospital.

Tang Yew Chung

Ph.D.

VP, Medical Affairs, Head of Early Detection

Tang Yew Chung is Vice President, Medical Affairs and Head of Early Detection at MiRXES where he oversees the strategic direction of clinician and researcher engagement and leads scientific and medical communications and partnerships. Yew Chung also heads our Japan market expansion and partnership efforts.

He has more than 10 years of experience in multi-disciplinary cancer research, including cancer genomics and systems biology, and has published 8 papers. Prior to joining MiRXES, Yew Chung spent nine years studying the functional genomics of breast cancer at Duke-NUS Medical School and was an Editor at Asian Scientist Magazine. He is constantly exploring innovative ways to communicate complex scientific information to the mass audience in a non-technical and engaging way.

Yew Chung has a PhD and MSc in Molecular Engineering of Biological and Chemical Systems from the Singapore-MIT Alliance, and a BEng in Chemical Engineering (Specializing in Biopharmaceutical Engineering) from the National University of Singapore.

Jeremiah Decosta

VP, Operations & Regulatory Affairs

Jeremiah Decosta is Vice President, Operations at MiRXES, where he leads the manufacturing strategy and oversees the management of quality control, quality assurance, supply chain and regulatory affairs.

Prior to this, Jeremiah served as the Production Director at APTA Biosciences, and was also Head of Operations at Vela Diagnostics. He has worked in MNCs and start-ups, and is both a leader and team player with management and hands-on experience.

Jeremiah holds a bachelor’s degree in Biomedical Science from the University of Bradford, UK.

Zhou Qiumei

VP, Manufacturing & Regulatory Affairs, MiRXES China

Zhou Qiumei is the Vice President, Manufacturing & Regulatory Affairs at MiRXES China. Qiumei oversees the overall manufacturing and production capabilities, as well as manages the regulatory affairs, quality control and quality assurance in MiRXES China.

She has management experience of more than 10 years having held positions in various biotechnology and medical device companies such as Anrei Medical Holding Company, Hangzhou Singclean Medical Products Co. Ltd., Hangzhou Medzone Biotech Company and Hangzhou NeuroPeptide Biological Science and Technology Incorporation Ltd. Qiumei is well-versed in the construction of Good Manufacturing Practices certified facility, establishment of quality management system, production process of medical devices, as well as familiar with the laws and regulations regarding medical devices and in-vitro diagnostic products in both China and Europe.

Qiumei holds a Master of Science in Biochemistry and Molecular Biology from Zhejiang Sci-Tech University.

Larbi Gallagher

VP, Strategy & Growth Operations

Larbi Gallagher is Vice President, Strategy and Growth Operations at MiRXES and oversees MiRXES’s U.S. business development operations.

Larbi has over 16 years of global cross-commercial leadership experience in biotech/life sciences where he worked in established companies including Illumina, Thermo Fisher Scientific Inc and Djinndustries in the U.S., China, Japan and Australia. Of the 16 years, he spent 10 years managing international teams in Asia Pacific. Larbi has a clear history of efficiency with organizational design and business execution, as well as a strong reputation for ethical behavior in China and respect and collaboration while in Japan. He is committed to helping his teams make breakthroughs in their projects or removing obstacles to their success.

Larbi holds a Master of Science in Plant Molecular & Cellular Biology, University of Florida, and a Bachelor of Science in Environmental Horticulture, University of Florida.

Ray Ong

Ph.D.

VP, Commercial, Head of Precision Oncology & Pandemic Response

Ray Ong is the Vice President,Commercial and Head of Precision Oncology & Pandemic Response at MiRXES where he drives the overall strategy for business development and sales of MiRXES’s products and services.

Before joining MiRXES, Ray was the Oncology Business Development Manager at ThermoFisher Scientific, India Pacific, where he supported the Clinical Sequencing Division efforts in the Oncology Segment with active engagement with pharma, testing labs and key oncologists. In 2019, he collaborated with the local lung cancer network to successfully establish a multiple pharma co-payment model for lung cancer patients in Malaysia. Ray has previously served as a product manager with Bio-Rad Laboratories and was involved in its entry into the molecular diagnostics space with EGFR T790M testing for Osimertinib.

Ray has a PhD in Neurobiology under the Department of Physiology with the School of Medicine at National University of Singapore.

Guy Afseth

Vice President, North America

Guy Afseth is Vice President, MiRXES North America. Guy is responsible for establishing key partnerships with leaders in biopharmaceutical, molecular diagnostics and academic institutions and supporting the incorporation of MiXRES technology into miRNA-based assay development of molecular diagnostics offering high value for patient care.

He has spent over 25 years in the Life Sciences and Molecular Diagnostics industries in technical, sales, product management and business development roles. Prior to MiRXES, Guy has held positions in business development, portfolio and product management and marketing in companies including Codex DNA, Roche Molecular Solutions, Gilson Inc., Thermo Fisher Scientific and Abbott Molecular. He is a passionate, customer-focused leader in life sciences and molecular diagnostics industries with broad technical and commercial abilities, and institutional knowledge gained from dominant diagnostic players.

Guy has a Master of Arts in Marketing Management from DePaul University, Chicago, Illinois and a Master of Science in Molecular Microbiology from Washington State University, Pullman, Washington.

Yoong Li-Foong

Representative Director & Country General Manager, MiRXES Japan

Yoong Li-Foong is the Representative Director and Country Manager of MiRXES Japan. Li-Foong led the setting up of MiRXES subsidiary in Tokyo, Japan, where she now heads the business development and market expansion, as well as overseeing the overall operations.

She has more than 13 years of research experience in USA and Japan, including genetics, development biology and cellular signaling, and has published eight papers. Prior to joining MiRXES, Li-Foong has accumulated more than 10 years of research experience in Japan’s largest national research institute, RIKEN, where she has also received the prestigious international fellowship award from Human Frontier Science Program. She is passionate about bringing MiRXES’s innovative disease early detection solutions, from lab to user, so that more people can be benefited from a better and earlier diagnosis.

Li-Foong has a PhD in Biochemistry from the National University of Singapore.

周砺寒博士

Ph.D.

联合创始人兼首席执行官

周砺寒博士是 觅瑞 的联合创始人和首席执行官。砺寒带领 MiRXES 从新加坡一家小型创业公司成长为在 RNA 技术和疾病早期检测行业的准独角兽,业务遍及全球。创立觅瑞之前,砺寒在 A*STAR 生物技术研究所领导的研究团队开发了一种用于生物标计物和发现治疗靶点研发的新型 microRNA qPCR 检测平台。2015 年,砺寒被《麻省理工科技评论》评为“ 35 岁以下创新者”。砺寒在新加坡国立大学杨潞龄医学院获得生物化学博士学位。砺寒撰写及合著了 20 多篇论文专著并发明了多项专利。

邹瑞阳博士

Ph.D.

联合创始人兼首席技术官

邹瑞阳博士是觅瑞的联合创始人兼首席技术官。瑞阳负责觅瑞的技术和诊断测试研发,并负责觅瑞中国的整体运营。成立觅瑞之前,瑞阳在新加坡科技研究局(A*STAR)旗下微小核酸指纹鉴定中心(MicroRNA Signature Identification Center)担任生物信息部负责人。瑞阳对科学和创新充满热情,专注于有应用转化潜力,并且能惠及大众的科技研发。瑞阳拥有新加坡-麻省理工联盟 (NUS-MIT) 的化学和制药工程博士学位。他在 2007 年获得天津大学与南开大学的化学与化学工程双学位。瑞阳已合著 10 余篇论文专著,并拥有 8 项专利和专利申请。

何豪杰 (Issac Ho)

首席投资官

何豪杰是觅瑞的首席投资官,负责企业发展、投资者关系以及医疗保健机构和金融机构的战略合作关系。加入觅瑞之前,Isaac 创立了 Singapore Health,随后创立的 VentureCraft Group是经新加坡政府认证的医疗保健和生物医学领域的投资和孵化基地。他在创业、投资和企业管理方面有着丰富的经验。在他的领导下,Venturecraft Group 被新加坡政府标准、生产力与创新局认证为生物医学科學行业加速计划中的孵化公司。Isaac 毕业于迪肯大学,获得营销和管理学士学位。

Choo Beng Lor

首席财务官

Choo Beng Lor 是觅瑞的首席财务官,负责有关财务、内审、公司管理和投资者关系方面的事务。他曾任浙能锦江环境控股有限公司财务总监,负责财务管理以及上市相关事项。此前,Beng Lor曾在 Cima NanoTech Pte Ltd、Sound Global Ltd 和 Sino Chemical Holdings Pte Ltd 等公司担任首席财务官长达11年。Beng Lor 毕业于新加坡南洋理工大学会计学专业。他是新加坡特许会计师协会的特许会计师。

Francine Wong

人力资源部总监

Francine Wong 是觅瑞的人力资源总监,负责制定和执行人力资源战略,以辅佐公司在人才管理、组织发展、绩效与奖励以及学习与发展上的业务计划和战略方向。  她之前是 A. Menarini Asia Pacific 亚太区人力资源总监,主管亚太区 13 个市场的人力资源。  Francine 在物流、工程和银行方面拥有多元的行业经验,其大部分经验集中在医疗保健行业,她曾担任通用电气医疗集团 (GE Healthcare) 东盟区人力资源主管和瑞思迈亚洲增长市场战略人力资源业务合作伙伴总监。  在 瑞思迈,她是全球人力资源领导团队中的一员,帮助制造中心规模增长了四倍,并支持了其扩张。Francine 毕业于南洋理工大学人力资源咨询专业,获得商学学士学位,并持有曼彻斯特大学的工商管理硕士学位。

David Capes 博士

Ph.D.

全球创新负责人

David Capes 是觅瑞的全球创新负责人,负责将觅瑞转型为全球创新企业。David 拥有超过 31 年丰富的生物医疗行业经验,包括一般性管理和战略、研发、创新、自生和刻意机会识别和开发、质量管理、法规事务管理、制造和销售等方方面面。他之前曾任 Becton-Dickinson (BD) 大亚洲地区的研发副总裁,领导战略创新团队,并为其新产品开发 (NPD) 组合建立“理念组合管理”发挥了重要作用。在他带领下,该新产品获批后营收超过预设目标五倍。在加入 BD 之前,他曾在 Pathway Biomed 和 Rockeby Biomed 担任高级管理职务。David 拥有科廷大学的药学博士学位,撰写和合著了超过 54 篇出版物,拥有两项美国专利。

Teo Cher Hwa

健康创新交付部高级副总裁兼首席战略官

Teo Cher Hwa 是觅瑞的健康创新交付部高级副总裁 (SVP) 兼首席战略官。Cher Hwa 推动觅瑞产品通过下游渠道进入新加坡的医疗保健系统。此外,作为首席战略官,他协助觅瑞的联合创始人兼首席执行官周砺寒博士监督从战略制定直至战略执行,并在关键决策、项目管理和落实方面与各职能的负责人密切合作。Cher Hwa 在融资、技术转让、产品开发以及电信和生物医学设备创新技术商业化方面拥有 20 多年的经验。他之前曾担任新加坡国家健康创新中心 (National Health Innovation Centre Singapore) 总监,也是该中心的创始成员之一。此前,Cher Hwa 是 A*Star 的 A*ccelerate Technologies 通信与医疗保健事业部的副总裁,负责监督医疗技术和通信领域的知识产权管理、许可、行业合作和转化资助项目等的技术转让。Cher Hwa 拥有谢菲尔德大学电子工程学士学位(一级荣誉)和曼彻斯特大学 MBA 学位。

Dan Headon

营销高级副总裁

Dan Headon is the Senior Vice President (SVP), Marketing at MiRXES. In his role as SP, Marketing, Dan will raise the awareness of MiRXES’s products to patients and customers by partnering closely with the Product, Commercial Operations and Medical Affairs’ teams in launching new products and refining the marketing strategy for MiRXES’s existing products.

Dan has more than 30 years of extensive experience in the biotechnology sector working for companies such as Biotech Australia, Millipore, Applied Biosystems and Illumina. Prior to joining MiRXES, he was the Director of Marketing for APAC at Illumina from 2008 to 2017, where he scaled the APAC marketing function from three to over 50 staff over a period of 10 years and contributed towards Illumina’s revenue growth in the region from USD 30 million per annum to over USD 500 million through a series of innovative marketing strategies.

Dan holds a Bachelor of Science degree from Macquarie University and a Graduate Diploma of Marketing from Monash University.

Cheng He 博士

Ph.D.

研发部副总裁

Cheng He博士 担任觅瑞的研发副总裁,他领导的研究项目旨在探索和开发组织、细胞和生物体液中的microRNA 生物标志物,以及将无细胞 microRNA 生物标志物产品化以用于液体活检。此前,Cheng He 是 A*STAR 生物加工技术研究所 (BTI) 的科学家。Cheng He 致力于用创新技术解决医疗保健问题,曾在多个跨学科领域工作,他曾开发纳米线传感器和肿瘤预后的 mRNA 临床研究。他拥有从上游研发以至下游产品化的经验。Cheng He 拥有新加坡国立大学电气工程博士学位和麻省理工学院材料科学硕士学位,以及南洋理工大学生物工程学士学位。

Cheong Jit Kong博士

Ph.D.

外部创新部负责人

Cheong Jit Kong 博士是觅瑞外部创新负责人,负责主要市场的外部研发利益相关者事宜。他还负责支持觅瑞 全球临床/科学研究以及真实世界研究。此外,Jit Kong 同时担任国立大学杨潞龄医学院的主要研究员、助理教授和医学院NUS ncRNA 核心机构负责人。Jit Kong 是多个新加坡国内和国际研究基金的获得者。他在癌症生物学方面的信号转导级联、癌症动物模型、抗癌药物的发现以及高通量 miRNA 表达筛选方面具有丰富的经验。Jit Kong 获得了新加坡国立大学 (NUS) 和哈佛大学 (美国) 哈佛医学院( HMS ) 的博士学位,师从 Stephen Kong Hsu I-Hong 和 Joseph Bonventre 教授。随后,他在杜克大学-新加坡国立大学医学院 David Virshup 教授的实验室进行了接受新加坡千禧基金会博士后研究。

Zhao Pan 博士

Ph.D.

产品副总裁

Zhao Pan博士 是 觅瑞 的产品副总裁,她负责领导觅瑞的产品和服务线的整体战略,并管理产品生命周期。此前,Pan 是 Lucence Diagnostics 的联合创始人和首席商务官。而在这之前,她在Vishuo Biomedical 和 Vela Diagnostics等多家公司负责商务拓展和现场实施。Pan 认为通过赋能医生可改善患者的治疗,她是精准医疗、基因检测和疾病早筛的倡导者。Pan 拥有新加坡国立大学研究生院分子及微生物学博士学位,最近又获得香港中文大学威尔斯亲王医院妇产科医学遗传学硕士学位。

Tang Yew Chung 博士

Ph.D.

科学/医学事务助理副总裁

Tang Yew Chung 博士是觅瑞科学和医学事务助理副总裁,负责科学和医学事务战略规划,并领导科学和医学的交流及合作事务。Yew Chung 也负责日本市场的拓展和合作工作。他拥有1十多年的多学科癌症研究经验, 包括癌症基因组学和系统生物学等,并发表了八篇论文。在加入觅瑞之前,Yew Chung 有九年的时间在杜克大学-新加坡国立大学医学院研究乳腺癌功能基因组学,也是《亚洲科学家杂志(Asian Scientist Magazine) 的编辑。他不断地探索以创新的方式向大众科普复杂的科学知识。Yew Chung 拥有新加坡-麻省理工学院联盟生物和化学系统分子工程博士和硕士学位,以及新加坡国立大学化学工程(生物制药工程专业)学士学位。

Jeremiah Decosta

生产和法规事务副总裁

Jeremiah Decosta 是觅瑞副总裁,负责制造和法规事务,他领导制造策略、质量控制、供应链和法规事务等。此前,Jeremiah 在 APTA Biosciences 担任制造总监,也曾任 Vela Diagnostics 的运营主管。他曾供职于多家跨国公司与创业公司,具有丰富的领导和管理经验以及极强的团队精神。Jeremiah 拥有英国布拉德福德大学生物医学科学学士学位。

Zhou Qiumei

觅瑞中国制造和法规事务部副总裁

Zhou Qiumei 是觅瑞中国的生产和法规事务部副总裁。Qiumei 负责觅瑞中国的整体生产制造和产能,以及法规事务、质量控制和质量保证。她拥有超过 10 年的管理经验,曾在多家生物技术和医疗器械公司任职,如 Anrei Medical Holding Company、杭州 Singclean 医疗制品有限公司、杭州铭众医疗器械有限公司、杭州纽龙生物科技有限公司。Qiumei 精通药品生产质量管理规范认证的建设、质量管理体系的建立、医疗器械的生产流程,并熟悉中国和欧洲有关医疗器械和体外诊断产品的法律法规。Qiumei 拥有浙江理工大学生物化学与分子生物学硕士学位。

Larbi Gallagher

战略与增长运营副总裁

Larbi Gallagher 是觅瑞战略和增长运营副总裁,负责觅瑞在美国的业务开发和运营。Larbi 在生物科技/生命科学领域拥有超过 16 年的全球跨商业领导经验,曾在美国、中国、日本和澳大利亚的知名公司工作,包括 Illumina、Thermo Fisher Scientific Inc 和 Djinndustries。在这16 年里,他有 10 年时间在亚太地区管理国际团队。Larbi 在组织设计和业务执行方面经验丰富,同时也可较好的适应中日两国的管理差异,他致力于带领团队在项目中突破或消除障碍并获得成功。Larbi 拥有佛罗里达大学植物分子和细胞生物学硕士学位以及佛罗里达大学环境园艺学学士学位。

Ray ONG 博士

Ph.D.

商业运营副总裁

Ray Ong 博士是觅瑞商业运营副总裁,负责推动觅瑞产品和服务的业务发展和销售的整体战略。在加入觅瑞之前,Ray 是赛默飞世尔科技印度太平洋地区的肿瘤学业务拓展经理,通过与制药公司、检测实验室和主要肿瘤学者的积极合作,协助临床测序部门在肿瘤方面的工作。2019 年,他与马来西亚肺癌网络合作,成功地为当地肺癌患者创立了多家制药公司共同支付模式。Ray 之前曾担任 Bio-Rad Laboratories 的产品经理,并参与了Osimertinib的EGFR T790M 产品 进入分子诊断领域的工作。Ray 拥有新加坡国立大学医学院生理学科系神经生物学博士学位。

Guy Afseth

觅瑞 美国业务开发部主管

Guy Afseth 是觅瑞美国的商务拓展部主管。Guy 负责与生物制药、分子诊断和学术机构等建立重要的合作伙伴关系,并致力于MiXRES 技术的推广,为患者护理提供高价值服務。他在生命科学和分子诊断行业从事技术、销售、产品管理和商务拓展长达 25 年。在加入觅瑞之前,Guy 曾服务于Codex DNA、Roche Molecular Solutions、Gilson Inc.、Thermo Fisher Scientific 和 Abbott Molecular, 曾担任业务开发、投资组合和产品管理以及营销等职位。他对生命科学和分子诊断行业充满热情,并是一位以客户为中心的领导者,他拥有广泛的技术和商业能力,并在行业内经验丰富。Guy 拥有伊利诺伊州芝加哥德保罗大学的营销管理硕士学位和华盛顿州立大学普尔曼分校的分子微生物学硕士学位。

Yoong Li-Foong

觅瑞日本经理助理兼代表董事

Yoong Li-Foong 是觅瑞 日本助理经理兼代表董事。Li-Foong 领导成立日本东京的觅瑞子公司,她负责商务和市场拓展,并监督整体运营。她在美国和日本有13 多年的研究经验,涉及遗传学、发育生物学和细胞信号领域,发表了 八 篇论文。在加入觅瑞之前,Li-Foong 在日本最大的国立理化学研究所积累了 十几 年的研究经验,在日本理化学研究所她还荣获了著名的人类前沿科学项目的奖学金。她致力于将觅瑞的创新疾病早期检测方案从实验室带给用户,令更多的人可以从更好、更早的诊断中受益。Li-Foong 拥有新加坡国立大学生物化学博士学位。